|Alma mater||Hadassah Medical School M.S. 1971; M.D. 1974 Technion-Israel Institute of Technology D.Sc|
|Known for||Ubiquitin-mediated protein degradation|
|Awards||Nobel Prize in Chemistry (2004) |
Aaron Ciechanover (/ / (listen) AH-hə-ROHN chee-HAH-noh-vair; Hebrew: אהרן צ'חנובר; born October 1, 1947) is an Israeli biologist who won the Nobel Prize in Chemistry for characterizing the method that cells use to degrade and recycle proteins using ubiquitin.
Ciechanover was born in Haifa, Israel on 1 October 1947. He is the son of Bluma (Lubashevsky), a teacher of English, and Yitzhak Ciechanover, an office worker. His mother and father supported the Zionist movement and immigrated to Israel from Poland in the 1920s.
He earned a master's degree in science in 1971 and graduated from Hadassah Medical School in Jerusalem in 1974. He received his doctorate in biochemistry in 1981 from the Technion – Israel Institute of Technology in Haifa before conducting postdoctoral research in the laboratory of Harvey Lodish at the Whitehead Institute at MIT from 1981 to 1984.
Ciechanover is currently a Technion Distinguished Research Professor in the Ruth and Bruce Rappaport Faculty of Medicine and Research Institute at the Technion. He is a member of the Israel Academy of Sciences and Humanities, the Pontifical Academy of Sciences, and is a foreign associate of the United States National Academy of Sciences. In 2008, he was a visiting Distinguished Chair Professor at NCKU, Taiwan. As part of Shenzhen's 13th Five-Year Plan funding research in emerging technologies and opening "Nobel laureate research labs", in 2018 he opened the Ciechanover Institute of Precision and Regenerative Medicine at the Chinese University of Hong Kong, Shenzhen campus.
Ciechanover is one of Israel's first Nobel Laureates in Science, earning his Nobel Prize in 2004 for his work in ubiquitination. He is honored for playing a central role in the history of Israel and in the history of the Technion – Israel Institute of Technology.
Ciechanover has served on the Scientific Advisory Boards of the following companies: Rosetta Genomics (Chairman), BioLineRx, Ltd, StemRad, Ltd, Allosterix Ltd, Proteologics, Inc, MultiGene Vascular Systems, Ltd, Protalix BioTherapeutics, BioTheryX, Inc., and Haplogen, GmbH.
Ciechanover is a member of the Advisory Board of Patient Innovation, a nonprofit, international, multilingual, free venue for patients and caregivers of any disease to share their innovations.